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Abstract
Enabling  vaccine  delivery  platforms  and  adjuvants  with  promising  attributes  for
malaria  vaccine  development  are  reviewed  within  the  framework  of  accessibility,
efficacy, clinical status, cost, and cold-chain considerations. An emphasis is placed on
commercially available platforms and adjuvants including virus-like particle, nanopar-
ticle,  microneedle,  and mRNA vaccine  delivery  platforms as  well  as  lipid  vesicle,
microparticle, and emulsion-based adjuvants. Strategies for addressing complications
of vaccine delivery in endemic regions due to concatenate vaccination and infection,
and  parasite  immune  avoidance  mechanisms  are  presented.  Additionally,  recent
findings regarding how malaria infection triggers inflammatory pathways and T cell
exhaustion  along  with  negative  impacts  to  the  development  of  effective  memory
responses are described in a context relevant to vaccine development.
Keywords: Plasmodium falciparum, malaria, adjuvant, vaccine, delivery platform, VLP,
virus-like particle, microneedle, mRNA, nanoparticle, microparticle, liposome, emul-
sion, nanoemulsion, TLR agonist, T cell exhaustion, PD-1, immune response, CSP
1. Introduction
Efforts to develop an effective malaria vaccine have been ongoing for decades. In order to
promote better coordination and acceleration of malaria vaccine development, the World
Health Organization (WHO) initiated a process that resulted in the Malaria Vaccine Technol-
ogy Roadmap, which was first published in 2006 [1] and updated in 2013 [2]. The vision in the
roadmap includes development of vaccines for Plasmodium falciparum and P. vivax to prevent
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disease, death, and malaria transmission as part of enabling malaria eradication efforts. As
per the updated Malaria Vaccine Technology Roadmap,  the goal  of  a  successful  vaccine
candidate is ≥75% protective efficacy over 2 years with no more than one annual booster that
can be administered to all age groups. Transmission-blocking vaccines were also included in
this development effort. Importantly, the Roadmap prioritized access to low cost GMP vaccine
manufacture for commercial production, which encompasses a direct pathway to licensure,
ability to manufacture at a large scale, as well as vaccine availability and ease of access,
inclusive of delivery platforms and adjuvants. With these considerations in mind, we review
enabling vaccine delivery platforms and adjuvants with favorable attributes, to both facilitate
the fusion of promising malaria targets with novel technology platforms and meet Roadmap
vaccine development, efficacy, and accessibility goals.
A brief overview of recent findings regarding development of immune responses during and
after malaria infection is relevant to vaccine development (particularly regarding parasite
immune evasion mechanisms that engage inflammatory pathways, promote T cell exhaustion,
and stimulate regulatory T cell expansion), as vaccination and malaria infection occur
concatenately in endemic regions. Traditionally, the intended outcome of any combination of
malaria vaccine target and adjuvant/delivery platform would be to elicit as strong of an
immunostimulatory response as possible to the Th1 and/or Th2 immune compartments.
However, studies of chronic disease in humans and mice, in the cancer and infectious disease
fields, have shown that magnitude of the immune stimulus may not be as important as the
balance of immune presentation to immune overreaction (e.g., regulatory T cell stimulation
and T cell exhaustion/ablation) [3–5]. Recent studies in rodent malaria models have signifi-
cantly increased our understanding regarding how chronic malaria infection can hamper
development of effective Th1 and Th2 immune responses as well as development of B and T
cell memory. For example, in a mouse model of severe malaria infection, it has been shown
that proinflammatory cytokines (IFN-γ and TNF) and pathways mediating the disease are
detrimental to development of humoral response by inhibiting/exhausting T helper cells [6].
That these cytokines are the same as those monitored in regards to enhanced cellular response
to many adjuvanted vaccines is of particular concern. Furthermore, in mouse malaria models,
chronic malaria infection triggers CD8+ T cell exhaustion (loss of T cell effector function)
through a programmed cell death-1 (PD-1) pathway [7, 8]. In humans, the state of T cell
exhaustion has been documented following numerous infections, during chronic infection, as
well as in cancer patients, with expression of PD-1 as a hallmark exhaustion [9]. Taken together,
these phenomena suggest an explanation for some of the difficulties encountered during
malaria vaccine development as well as provide insight into why vaccine-induced protective
immunity quickly wanes. A knowledge base on preventing T cell exhaustion has been
developed in the therapeutic cancer vaccine field, which can be used as a launching point for
how to address this issue in malaria vaccine development. One of the key areas of interest is
the use of adjuvants to downregulate pathways leading to T cell exhaustion (e.g., PD-1 and
LAG-3 inhibitors) [10–12]. Therefore, we suggest that the information presented herein be
considered in the context of careful characterization of the mode of action for the combined
antigen and adjuvant/delivery technology to overcome the evolving hallmarks of malaria
immune evasion.
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1.1. Enabling vaccine delivery platforms
A range of novel vaccine delivery platforms are described herein, including those that can
accommodate different antigen/immunogen formats such as recombinant proteins, peptides,
epitopes, and/or nuclei acids. Many of these platforms can deliver multiple antigens and in
different formats, simultaneously. In describing these platforms, we included state-of-the-art
technologies with the potential for major impacts to vaccine delivery where the regulatory and/
or licensure pathways may not yet be defined. As there are a significant number of published
preclinical and clinical studies on different viral vectored malaria antigens (e.g., adenovirus
and modified vaccinia Ankara (MVA) vectors), these platforms have not been detailed herein,
but have been recently reviewed elsewhere [13–15]. In addition, several particulate-based
platforms that have been used in combination with malaria candidate vaccines, but not
described here, have been recently reviewed [16].
1.2. Virus-like particles
The ability of viral capsid proteins to self-assemble and incorporate foreign antigens has
been exploited in the development of virus-like particles (VLPs) as a vaccine delivery
platform [17, 18]. While many VLP platforms for human pathogens have been developed
and utilized to deliver native epitopes of the subject virus, other VLP platforms can be used
to deliver foreign epitopes; only the latter is discussed herein. Platforms capable of integrat-
ing foreign epitopes include human pathogens (e.g., hepatitis B virus (HBV) and human
papillomavirus) and many nonhuman pathogens (e.g., bacteriophages, plant viruses, and
animal viruses). Foreign antigens can be incorporated into VLPs by genetic modification of
the capsid protein at one or more sites or by chemical conjugation of antigen to the capsid
protein. Immunogens can also be encapsidated within the VLP lumen. Even with these
modifications, capsid proteins can retain the structure and morphology of the originating
virus. VLPs are known to induce strong humoral and cellular immune responses as foreign
antigens are displayed in a repetitive manner on VLPs, which boost immune responses by
facilitating cross-linking of immunoglobulin receptors and B cell activation; VLPs are easily
taken up by antigen-presenting cells that ultimately lead to cytokine production, stimulation
of CD4+ T helper cells, and induction of potent cytotoxic immune responses through cross-
presentation to cytotoxic CD8+ T cells [18–24]. For most VLPs, single-stranded RNA (ssRNA)
is packaged within the particles during assembly. The presence of ssRNA is thought to
enhance immunity, as this is a natural ligand for Toll-like receptor (TLR) 7 and TLR8 [25].
Of note is that the described plant-based VLP platforms do not meet a strict definition of
VLP as they are infectious to and propagate in the organism in which they are grown (but
not in humans). For simplicity, and as these platforms are often identified as VLPs in the
literature, they are presented together in a single section.
The main drawback of VLP-based vaccines is size constraints of the foreign antigen incorpo-
rated or fused to capsid protein, which is dependent on the specific VLP platform. Note that
larger antigens can be chemically conjugated to some capsid proteins; however, this is also a
drawback as the antigen and capsid must be expressed and purified separately for conjugation,
which can elevate cost. Currently, three VLP-based malaria vaccine candidates have been
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evaluated in the clinic, and one of these was recently approved for use in humans. These are
RTS,S (tradename Mosquirix when in combination with AS01), ICC-1132, and Pfs25 VLP-
FhCMB, which are each described below. A recent review of the different GlaskoSmithKline
(GSK) adjuvants (AS01, AS02, etc.) can be found elsewhere [26].
1.2.1. Hepatitis virus VLPs
Viruses of the family Hepadnaviridae, including the human pathogen HBV, can be utilized as
vaccine delivery platforms. These viral particles have both an outer lipid envelope containing
a surface antigen (e.g., HBsAg) as well as a nucleocapsid composed of a core protein (e.g.,
HBcAg). Both the surface protein and core protein can accept foreign peptides and thus be
utilized as VLP-based vaccine delivery platforms. RTS,S is composed of the repeat and C-
terminal regions of P. falciparum circumsporozoite protein (PfCSP) fused to hepatitis B virus
surface antigen (HBsAg) and has been licensed in combination with AS01 by the European
Medicines Agency (EMA). The vaccine candidate ICC-1132 is comprised of the hepatitis B virus
core protein (HBcAg) with PfCSP T cell and B cell epitope insertions. ICC-1132 has been tested
in multiple clinical studies [27–30]; however, upon controlled human malaria challenge
(CHMI) of vaccinees administered with ICC-1132 formulated in Montanide, no sterile
protection was seen [30].
Core protein-based VLPs possess a number of favorable characteristics for vaccine develop-
ment as compared to surface protein-based VLPs. These include the ability of the recombinant
core protein to self-assemble into VLPs, flexibility of the expression system, and increased
immunogenicity of the core protein as compared to the surface protein [31–34]. Considerations
of immune tolerance issues when using VLPs based on the human pathogen HBV are also
important given the number of chronic HBV carriers worldwide. Additionally, as antibodies
to the HBcAg serve as the basis for HBV diagnostics, widespread use of HBcAg-based VLPs
may compromise use of anti-HBc antibodies to diagnose infection. These concerns have been
addressed through use of nonhuman pathogenic hepadnaviruses in VLP platform develop-
ment, including viruses that infect rodents and ducks [35–37]. In addition to RTS,S and
ICC-1132, which are VLPs based on the human hepatitis B virus, a woodchuck hepatitis B virus
VLP platform (WHcAg) containing PfCSP T cell and B cell epitopes (developed by VLP
Biotech) has shown promise in challenge studies with a rodent malaria model where 80–100%
protection was seen with different formulations [38]. In this same study, a WHcAg VLP
carrying P. vivax circumsporozoite protein (PvCSP) repeat epitopes was used for challenge
with a rodent malaria model and 100% protection was seen. A comparative study of antige-
nicity and immunogenicity of different rodent hepatitis virus core proteins (woodchuck,
ground squirrel, and artic squirrel) and HBcAg demonstrated that rodent core proteins are (1)
equal in immunogenicity to, or more immunogenic than HBcAg for both B cell and T cell
responses, (2) not significantly cross-reactive with the HBcAg for B cell responses and only
partially cross-reactive with HBcAg for T cell (CD4) responses, and (3) competent to function
as vaccine carrier platforms for heterologous, B cell epitopes [36, 39]. In consideration of cost,
WHcAg VLPs can be easily expressed at high levels in E. coli. In addition, this platform can
Current Topics in Malaria390
accommodate insertion of foreign sequences at multiple sites within the coat protein and large
inserts at both the N- and C-termini. Note that this platform has not yet been tested in the clinic.
1.2.2. Bacteriophage VLPs
VLPs based on ssRNA bacteriophages can be used as vaccine delivery platforms through
conjugation of foreign antigens to the coat protein, encapsidation of foreign antigens within
the VLP, or genetic insertion of foreign sequences into the coat protein. One application of the
last is creation of VLP-based peptide display libraries by the University of New Mexico (based
on MS2, PP7, and AP205 bacteriophage VLP platforms) using a series of plasmid vectors that
allow insertion of high complexity random sequence peptides into the coat protein enabling
construction of libraries with up to 1010 to 1011 unique random sequence peptide VLP clones
with inserts from 6 to 20 base pairs in length [40, 41]. Biopanning can be performed on these
libraries using neutralizing or inhibitory antibodies to affinity select VLPs containing mimo-
topes—peptide sequences that mimics the structure of epitopes. As opposed to traditional
peptide display technologies, affinity selected bacteriophage VLPs can be used directly as
immunogen without modification. For example, a VLP mimotope to reticulocyte-binding
protein homologue 5 (RH5) found through affinity selection of MS2 libraries using a mono-
clonal antibody able to block parasite invasion of erythrocytes (in vitro via growth inhibition
assay) was shown to elicit inhibitory antibodies when administered to mice as an immunogen
[42]. In addition, MS2 VLP library affinity selection has also been performed with two anti-
AMA-1 monoclonal antibodies [42, 43]. Of note is that Agilvax LLC (a startup that was spun
out of the Science & Technology Corporation at the University of New Mexico) holds an
exclusive license to commercialize this technology for vaccines and immunotherapies based
on the MS2 and AP205 VLP platforms. The MS2 VLP platform can also be used to encapsidate
RNA and RNA-modified cargo [44]. Similar to the Qbeta VLPs, foreign antigen can be
conjugated to AP205 VLPs [45]. Additionally, while most bacteriophage VLPs can only tolerate
small foreign insertions, relatively large insertions are tolerated by the AP205 platform [46].
This has been exploited to create a platform whereby antigens can be irreversibly bound to
and displayed on AP205 VLPs by simple mixing using SpyCatcher and SpyTag; further, AP205
VLPs utilizing the SpyCatcher/SpyTag system and displaying Pfs25 (a transmission-blocking
vaccine target) are immunogenic in mice [47, 48]. Note that use of the SpyCatcher/SpyTag
technology might easily be extended to several other platforms included here, in particular to
nanoparticles and lipid vesicle-based platforms; however, it will be important to understand
if this technology can meet regulatory requirements for clinical use.
1.2.3. Plant-based virus VLPs
A number of plant viruses have been developed into replication-competent platforms whereby
VLPs can infect and replicate in plants (generally tobacco or spinach), but not in humans. Two
of the more advanced platforms include alfalfa mosaic virus (AlMV) and tobacco mosaic virus
(TVM), both of which can be produced at high levels in plants [49]. While the benefits of
biologics production in plants include the ability to produce large quantities of material with
relatively low cost starting materials, there are logistical challenges in housing and transfecting
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plants on a large-scale under conditions that meet GMP requirements as well as development
of downstream purification processes to recover VLPs from fibrous plant material [50]. Of note
is that significant improvements have been made in plant cell culture for expression of
pharmaceutical products (conducted in bioreactors), which has the potential to alleviate some
of these challenges and increase the feasibility of using plant VLPs platforms for large-scale
vaccine production [50, 51]. Malaria vaccine research efforts have included development of a
AlMV VLP containing Pfs25 by Fraunhofer USA Center for Molecular Biotechnology [52],
which has been tested in a phase I clinical trial (ClinicalTrials.gov Identifier: NCT02013687);
however, results of the trial have not yet been published.
1.3. Polymeric nanoparticle delivery platforms
Polymeric nanoparticles share many of the immunological advantages of VLPs in that their
size and structure are similar to that of a pathogen, which leads to interaction with antigen
presenting cells [53]. An additional attribute of polymeric nanoparticles is that these can be
tailored to a specific purpose through adjusting physical attributes such as size, shape, and
charge as well as customizing the type and concentration of polymer [54]. A number of
different nanoparticle-based vaccine delivery platforms are available, some of which have been
used in the clinic and some of which have thus far only been assessed in animals. The main
components of these platforms are biodegradable polymers/composites that function to create
a depot for antigen presentation. Immunostimulators can also be incorporated into these
delivery platforms. Antigens may be encapsulated or bounded by covalent or noncovalent
bonds.
1.3.1. PLGA nanoparticle delivery platforms
Poly-DL-lactide-co-glycolide acid (PLGA) is a biodegradable polymer approved for human
use by FDA for several indications. Published applications of PLGA nanoparticles in regards
to malaria vaccine development include the targets Pfs25 and PvCSP [55, 56]. PLGA nanopar-
ticle delivery platforms of interest for malaria vaccine development include Selecta Bioscien-
ces’ synthetic vaccine particle (SVPTM) platform and Orbis Biosciences StratumTM platform. The
SVPTM platform in combination with TLR7/8 and TLR9 agonists can enable robust cellular and
humoral immune responses, and is flexible regarding how antigens are incorporated [57]. The
StratumTM technology is based on PLGA microspheres that encapsulate aqueous material
(including antigens) and degrades in a controlled manner to permit delayed release of
encapsulated material [58, 59]. For example, this platform can enable provision of both prime
and booster antigen within a single administration with the booster contained in extended
release microspheres that degrade 30 days after administration. Clinical studies have been
conducted on PLGA-based platforms from both Selecta and Orbis.
1.3.2. Multilayer nanofilm-based nanoparticles
Artificial Cell Technologies, Inc. (ACT) has developed an innovative method for producing
nanoparticle vaccines utilizing artificial biofilms comprised of oppositely charged polymers
and target antigens constructed on solid CaCO3 cores (nonimmunogenic carrier) using layer-
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by-layer (LbL) fabrication. This platform can accommodate multiple target antigens applied
at different layers (depths) within the biofilms as well as immunostimulators, as needed for
optimizing the immune response. Additionally, the biolayers can include innate immune
stimulants to increase vaccine potency. Biofilm generation and LbL fabrication of nanoparticles
have been previously described [60–62]. Of note is that experimental studies have shown that
proteins/polypeptides are stabilized in nanofilms by noncovalent interactions, and secondary
structure is maintained during the manufacturing process [62]. Additionally, disulfide bonds
between cysteine-containing peptides increase nanofilm stability, mimicking the stabilization
of the native protein structure [62]. Several ACT nanoparticle constructs, including different
B and T cell epitopes of PfCSP, have been developed and tested in mice with encouraging
results [63]. While this platform has not yet been assessed in the clinic, ACT is fast approaching
intuition of a phase I study with this platform.
1.4. Microneedle platforms
Recent advances have increased interest in intradermal/transdermal vaccine delivery due to
an improved understanding of the high immune response achievable within the skin, based
on plasticity and high numbers of antigen-presenting cells (APCs) within this tissue, including
Langerhans cells, dendritic cells, and macrophages [64–66]. Traditional intradermal vaccine
delivery, using the Mantoux or skin scarification methods, requires special training to perform
correctly and can be inaccurate regarding the dose of vaccine that is delivered or difficult to
achieve based on volume limitations (skin scarification). Therefore, platforms that provide easy
and accurate transdermal delivery of vaccines are of high interest [67, 68]. Microneedle arrays
described herein are solid-state platforms that either integrate vaccine components into a
biodegradable polymer, which is subsequently formed into an array, or are manufactured from
nonbiodegradable materials into an array and then coated with vaccine components. In either
case, size and length of the microneedle array is controlled so that temporary pores are created
in the stratum corneum (the protective outer layer of the skin), and the vaccine is administered
to the desired depth. In addition to the benefit of “needleless” administration, the depth at
which microneedles penetrate does not reach underlying blood vessels or pain receptors.
Stabilization of antigens and adjuvants on or within the microneedle array is also of benefit,
particularly in regards to cold-chain requirements. One potential drawback of these platforms
is that relatively high concentrations of antigen and adjuvant must be possible in order to
achieve a relevant dosing range for most vaccines. Also of note is that development costs for
microneedle platforms that incorporate antigens are higher than those where antigens are
coated on the microarrays. In addition, consideration must be given to the administration
device used to place the array regarding cost and ease of use. However, cost savings are
achieved with these platforms because a needle and syringe is not required for administration.
Viral vectored ME-TRAP, PbCSP, and PyMSP-1 have been assessed with silicone microneedle
arrays in mice where increased immune response to the target antigen (compared to the vector)
and protective efficacy were found [69–71]. However, better responses were found using a
mixed administration regimen where antigen(s) were first given via the microneedle platform
and then boosted via the intradermal route. For these studies, antigen was applied to the skin
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just prior to application of the microarray rather than being incorporated into or coated on to
the microneedle array itself.
1.4.1. Natural polymeric microneedles
Silk fibroin is a biocompatible, biodegradable block copolymer that self-assembles into β-
sheets separated by flexible hydrophilic spacers. This natural polymer is approved by FDA for
human use in medical devices such as wound dressings and sutures, and GMP grade silk
fibroin is available from Vaxess Technologies. Significant progress has been made by Vaxess
in developing a consistent, repeatable manufacturing process for silk fibroin microneedles [72].
Additionally, several protein immobilization strategies can be used with this polymer includ-
ing adsorption, covalent bonding, entrapment, and encapsulation [73]. One attribute of this
platform that is highly attractive for malaria vaccine development is that silk fibroin micro-
needles can be designed such that an initial bolus of vaccine is delivered upon administration
followed by low-level sustained release of vaccine over a period of several weeks or longer [74].
Note that this microneedle platform has not yet been tested in the clinic.
1.4.2. Synthetic polymeric microneedles
Microneedle arrays can also be constructed from synthetic biodegradable polymeric materials
such as PLGA. Corium International has a vaccine-in-tip platform where antigen and adjuvant
are combined with MicroCor excipients and then the solution is cast into molds to create the
microstructure array (MSA) [75]. A PLGA backing layer is applied and the patch integrated
into an applicator. The MicroCor platform is designed such that the needles fully dissolve over
a period of several minutes after which the backing is removed. Arrays can also be constructed
from nonbiodegradable polymers, which are then coated with antigen and adjuvant. Such a
platform is available from 3M’s drug delivery systems division whereby arrays are molded
from medical grade liquid crystalline polymer and substances (antigens, adjuvants, etc.) are
coated on the microneedles using a dip coating process [76]. This type of array is designed to
be left in situ for a short period of time and then removed once the coating has dissolved. Note
that liquid crystalline polymer is not biodegradable. Microneedle platforms from both Corium
and 3M have been tested in the clinic.
1.5. mRNA-based vaccine delivery platforms
Recent advances in mRNA vaccine delivery have elevated these platforms to the point at
which feasibility of mRNA-based vaccines has been demonstrated in the clinic. The Cure-
Vac RNActive platform uses mRNA for vaccine delivery and relies on sequence modifica-
tions at the 5′ and 3′ ends to enhance protein expression and inclusion of a protamine
sequence to increase immunogenicity [77]. An RNActive prostate cancer vaccine has been
tested in the clinic with encouraging results regarding safety and immunogenicity, where
induction of both Th1 and Th2 responses was seen [78]. There are significant advantages
in using a nucleic acid-based platform including (1) the cost benefits of neither having to
manufacture/purify antigen nor formulate with adjuvant, (2) the possibility for develop-
ment of multivalent vaccines without concerns regarding formulation, and (3) quick man-
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ufacturing speeds where gene synthesis to completion of GMP production can take less
than 2 months. A parallel mRNA-based delivery platform has been developed by Mod-
erna; however, relatively limited information is available regarding Moderna’s mRNA
Therapeutics™ platform with the published studies relating to injection of mRNA into the
heart (in a mouse model) to treat myocardial infarction [79, 80].
1.6. DensigenTM platform
The DensigenTM platform (available from Altimmune) is based on rationally designed long,
fully synthetic peptides (30–40mers) containing natural clusters of CD4+ and CD8+ T cell
epitopes (termed densigens). A proprietary bioinformatics approach is applied to select the
most immunogenic and conserved domains. Densigens are conjugated to a fluorocarbon
moiety, which allows the densigens to self-assemble into micelle-based nanoparticles. The self-
adjuvanting properties of densigens are thought to be attributed to persistence of the nano-
particles at the administration site (depot effect) and resistance of the nanoparticles to
proteolytic degradation [81]. Multiple densigens can be incorporated into a single formulation.
A Phase I clinical study with a densigen-based influenza vaccine demonstrated good immu-
nogenicity to all six peptides contained in the vaccine (across divergent influenza strains) [82].
In addition, a Phase 1 study of an HBV therapeutic densigen vaccine (HepTcell, which is
composed of nine densigens) is ongoing (clinicaltrials.gov identifier: NCT02496897).
2. Enabling vaccine adjuvant platforms
Malaria vaccine enabling adjuvant platforms and immunostimulators are detailed in this
section. Many of these can be combined with different immunogen formats and vaccine
delivery platforms. We describe novel adjuvants as well as those where studies have been
performed with malaria vaccine candidates. Also noted is if an adjuvant has been or can be
combined with additional immunostimulators. Similar to the vaccine delivery platforms, we
included state-of-the-art technologies where the regulatory and/or licensure pathways may
not yet be defined.
2.1. Lipid vesicle-based platforms
Several different classes of lipids can be incorporated into vesicle-based vaccine adjuvant and
delivery platforms. These include traditional liposomes (phospholipids as well as anionic,
neutral, and cationic lipids from bacteria and eukaryotes), lipids derived from viral envelopes
(virosomes), and lipids from Archaea (archaeosomes). The versatility and plasticity of lipid
vesicle-based platforms are a major advantage as liposomal compositions can be customized
to achieve desired characteristics including lipid type(s), charge, size, antigen association type,
and inclusion of adjuvants and immunostimulators [83, 84]. Depending on the chemical
properties of the liposomes, antigens may be entrapped in the aqueous core, intercalated into
the lipid bilayer, and/or attached to the liposome surface by adsorption or conjugation.
Additionally, different antigens/adjuvants can be combined to tailor liposomal vaccines for
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specific applications [85, 86]. In general, these systems provide adjuvant activity by enhancing
antigen delivery to effector cells and/or by potentiating immune responses. Of note is that some
of the platforms in this section can serve as both adjuvants as well as delivery platforms,
depending on how antigen is incorporated. A comprehensive review of liposome vaccine
delivery platforms is provided in [87].
2.1.1. Aqueous liposomal platforms
Several aqueous liposomal platforms have been built around the capabilities of cholesterol
to stabilize lipid bilayers and QS-21 to create pores in lipid bilayers through association
with cholesterol. In addition to these properties, QS-21 has also been shown to stimulate
Th1-type responses and production of antigen-specific cytotoxic T lymphocytes (CTLs)
[88]. The molecular stability of QS-21 is increased when incorporated into liposomes [86],
as free molecules undergo deacylation above pH 6 and at temperatures problematic for
vaccine administration in warm climates where cold-chain may not be maintained [88].
Aqueous liposomal formulations containing QS-21 provided in a format that can be di-
rectly mixed with antigen include AS01 from GSK (which also contains monophosphoryl
lipid A – MPLA), GLA-LSQ developed by IDRI (which contains a synthetic form of
MPLA known as GLA), ALF-Q developed by WRAIR (which contains MPLA), and Ma-
trix-M from Novavax, previously known as AbISCO-100 (which is a unique 40-nm-sized
complex and can be combined with immunostimulators such as TLR agonists [89]). These
adjuvants are known to promote elicitation of both Th1 and Th2 immune responses [86,
90, 91]. One of the biggest drawbacks for several of these adjuvants is limited access/avail-
ability. However, GMP grade MPLA and QS-21 are available from Avanti Polar Lipids,
Inc. and Agenus Inc., respectively. In addition, GMP grade lipids suitable for liposomal
preparations are available from Avanti Polar Lipids.
Multiple clinical studies combining malaria vaccines/candidates (RTS,S, LSA-1, AMA-1,
MSP-1, and CelTOS) with this class of adjuvants have been performed [16]. The different levels
of protection seen with RTS,S/AS01 are well documented in the literature, and therefore not
reviewed here. A high level of protective efficacy has not been found with any of the other
malaria antigens combined with AS01, which has been recently reviewed in Ref. [16]. Preclin-
ical studies have been conducted with full length PfCSP recombinant protein adjuvanted with
GLA-LSQ where 40% sterile protection was seen upon challenge in a mouse malaria model
[92]. This adjuvant has also been used in combination with PfCelTOS recombinant protein
where a statistically significant reduction in liver load was found in challenged mice [93]. In
addition, a clinical study with GLA-LSQ and the placental malaria vaccine candidate PAMVAC
(VAR2CSA) has been registered on clinicaltrials.gov (identifier: NCT02647489); however, no
published information is available. ALF-Q is a relative newcomer, and there are currently no
published studies using ALF-Q in combination with malaria vaccine candidates. Matrix-M has
been tested in preclinical studies with a variety of antigens including viral-vectored Pv Duffy
binding protein (DBP) vaccine candidates. High levels of in vitro erythrocyte binding inhibition
(>90%) were achieved with Matrix-M formulations in this study [94]. Additionally, Matrix-M
has been assessed in a Phase I clinical study in combination with chimpanzee adenovirus 63
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(ChAd63) ME-TRAP and MVA ME-TRAP (ClinicalTrials.gov identifier: NCT01669512);
however, study results have not yet been published.
A platform related to Matrix-M and also comprised of lipids, cholesterol, and QS21 is im-
mune stimulating complex (ISCOM) technology. ISCOMs are spherical open cage-like
structures formed by cholesterol binding QS-21 and then stabilized with phospholipids
[95]. Similar to Matrix-M, ISCOMs have a mean diameter of ~40 nm; however, this tech-
nology incorporates antigens into the ISCOM such that they are displayed in a multimeric
fashion on the particles. ISCOMs are known to traffic antigen into the cytosol of dendritic
cells, stimulate both Th1 and Th2 immune responses, and link innate and adaptive im-
mune responses in vivo in a MyD88-dependent manner [96, 97]. The major drawback of
this platform is that the type and amount of antigen displayed can be limiting; however,
researchers have developed additional methods for incorporating antigen into ISCOMs,
including using cationic ISCOMATRIX particles to attract anionic proteins, adding a lipid
tail to the antigen, or using a fusion protein strategy to add hydrophobic peptide tags to
the antigen [98]. Although modification of a vaccine candidate for inclusion in such a plat-
form can add a layer of complexity and additional expense to the development process,
ISCOMs might be of interest to adjuvant malaria immunogens containing a GPI-anchor.
No studies with ISCOMs and GPI-anchored proteins were found in the literature. ISCOMs
are commercially available from CSL Behring as ISCOMATRIX.
Another aqueous liposomal platform of potential interest is the adjuvant CAF01, developed
by Statens Serum Institute. A clinical study conducted with this adjuvant demonstrated long-
lived Th1 responses over a 3-year monitoring period (ClinicalTrials.gov identifier:
NCT00922363) [99]. This adjuvant is comprised of two synthetic components, cationic lipo-
somes and a glycolipid immunomodulator (synthetic mycobacterial cell wall cord factor). In
a recent preclinical mouse study, five approved or clinically tested adjuvants (Alum, MF59®,
GLA-SE, IC31®, and CAF01) were each combined with antigens from M. tuberculosis, influ-
enza, and chlamydia and compared head-to-head [100]. Of the five adjuvants tested, CAF01
was the only adjuvant to elicit a Th1 immune response when formulated with each of the three
antigens. In addition, the CAF01 formulation demonstrated the highest reduction of M.
tuberculosis and Chlamydia trachomatis in challenge models. However, in most cases, the
humoral response elicited was similar to the no adjuvant and/or alum formulations. Note that
MF59®, GLA-SE, and IC31® are discussed in subsequent sections.
2.1.2. Lipid-in-oil platforms
The DepoVax™ platform, developed by ImmunoVaccine Inc., contains lipids, cholesterol, oil,
emulsifier, and an immunostimulant (e.g., polyIC or Pam3Cys) [101]. This unique lipid-in-oil
platform is designed to present antigen(s) and adjuvant(s) at a long lasting depot that
effectively attracts APCs and from which antigen is released over an extended period of time,
from weeks to months [102]. Based on this long lasting depot, a single dose of vaccine formu-
lated in DepoVax has been shown to be superior to multiple doses of the same vaccine
formulated in traditional adjuvants [103, 104]. In addition, DepoVax has been shown to not
only promote Th2 responses, but also enhance Th1 immune responses without triggering
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regulatory T cell [101]. DepoVax has been used in the clinic as part of a Phase I/II study for a
cancer vaccine (ClinicalTrials.gov identifier: NCT01095848) [105]. Of note is that there are no
aqueous components in this formulation; therefore, antigen is lyophilized for use with
DepoVax and components are mixed and emulsified prior to administration using materials
provided as part of an administration kit.
2.1.3. Virosomes
Virosomes are liposomes prepared by reconstituting virus envelope phospholipids. Those
from influenza virus are the most common with the virosome physicochemical properties
modulated by the amount and type of lipids used [106]. In contrast to liposomes, virosomes
can contain functional viral glycoproteins (i.e., influenza virus hemagglutinin and neurami-
nidase) within the phospholipid bilayer membrane, which enhance immunogenicity. Addi-
tionally, virosomes can induce both B and T cell responses through antigen presentation in the
context of both MHC-I and MHC-II [87, 106, 107]. Antigen can be encapsulated within the
virosomes, conjugated to phospholipids, or adsorbed to the virosome surface [108]. Malaria
antigens have been incorporated into influenza virosomes including epitopes from AMA-1,
CSP, MSP-3, and GLURP [109–111]. Clinical studies were performed with virosomes contain-
ing an AMA-1 peptide from domain 3 (PEV301) and a CSP repeat region peptide constituting
constrained NPNA units (PEV302). In a Phase 1a trial, volunteers immunized with PEV301,
PEV302, or a combination of the two (PEV301 + PEV 302) had good seroconversion and long-
lived humoral responses when assessed at a 1-year follow-up [112–114]. A Phase 1b trial was
conducted in a malaria-endemic area where adults and children were immunized with PEV3B
(a formulation including both the subject AMA-1 and CSP epitopes) or a comparator virosome-
based vaccine to influenza, Inflexal®V [115]. While not statistically significant, the malaria
incidence rate in children administered PEV3B was lower than children given Inflexal®V (67%
versus 80%, respectively) over the 1-year follow-up period.
2.1.4. Archaeosomes
Species of the domain Archaea contain unique polar lipids that have adjuvanting proper-
ties when used as liposomes (archaeosomes) containing encapsulated antigens. The lipid
backbones found in Archaea have a higher resistance to acid hydrolysis compared to those
from Eukarya and Bacteria, and surface tension and permeability characteristics of archaeo-
somes differ in comparison to traditional liposomes; these properties are also thought to
increase adjuvanting potential of archaeosomes [116]. The type of immune response gener-
ated with archaeosomes can be manipulated by changing composition of the head groups
attached to archaeol, and lipids from some Archaea have been used to chemically synthe-
size additional lipid types with interesting characteristics [117, 118]. Several studies with
archaeosomes and encapsulated ovalbumin (for cancer applications) have shown elicita-
tion of both Th1 and Th2 immune responses as well as the ability to modulate the im-
mune response by varying the types of polar lipids within the archaeosomes [117–119]. As
this is a relatively new platform, a pathway to regulatory approval for clinical testing and
licensure is needed.
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2.2. Polymeric microparticle-based adjuvants
AdvaxTM (developed by Vaxine) is a microparticle‐based adjuvant comprised of microcrystal‐
line delta inulin, a plant‐derived polysaccharide. Of note is that delta inulin is insoluble at body
temperature. This adjuvant generates Th1 and Th2 immune responses and activates the
alternative compliment pathway [120]. However, AdvaxTM does not activate nuclear factor‐
kappa B (NFkB) so an inflammatory response is not seen with this adjuvant [121]. Given the
mounting data regarding the ability of malaria to hinder development of effective immune
responses, adjuvants that do not trigger inflammatory responses are of interest, particularly
for use in malaria‐endemic regions. Although there are no published studies with AdvaxTM
and malaria antigens, preclinical assessments have been conducted with a variety vaccine
candidates formulated in this adjuvant [121]. In addition, this adjuvant has been assessed in
multiple clinical studies [122, 123].
2.3. Emulsion-based adjuvants
All of the adjuvants described in this section are oil‐in‐water emulsions. Those that include
solvents and surfactants form nanoemulsions, which facilitate antigen uptake by dendritic
cells [124]. Formulation of malaria vaccines with emulsion‐based adjuvants is of interest in
part because there are examples of a high level of sterile protection in clinical studies with
CHMI challenge when RTS,S was combined with an oil‐in‐water emulsion‐based adjuvant
[125, 126]. The GSK adjuvants AS02 and AS03 are both oil‐in‐water emulsions. AS03 contains
squalene, vitamin E, and Tween 80, while AS02 contains these components plus MPLA and
QS21. In a clinical study with CHMI where RTS,S was combined with either AS02 or AS03,
sterile protection was seen in 6/7 (86%) volunteers given RTS,S/AS02, and 2/7 (29%) volunteers
given RTS,S/AS03 [126]. However, 6 months after the last vaccination only 1/5 (20%) of the
volunteers given RTS,S/AS02 showed sterile protection upon a second CHMI [125]. For these
volunteers, the factors contributing to loss of protective efficacy in such a short period of time
is unclear but may relate to challenge and the ability of malaria parasites to compromise
development of long‐term immunity. In light of these and similar results, improvements in
sustaining established immunity must be made regarding development of an effective malaria
vaccine.
2.3.1. MF59
MF59 is an oil‐in‐water nanoemulsion that consists of squalene oil, Tween 80, and sorbitan
trioleate (Span 85). MF59 (available from Novartis) is licensed in Europe as a clinical vac‐
cine adjuvant for influenza and has been intramuscularly administered to millions of peo‐
ple ranging in age from children to elderly adults. This adjuvant has been assessed in
animal studies with MSP‐1 and PvDBP malaria antigens; however, immunogenicity and
binding assay (PvDBP) results were poor in comparison to other adjuvants [127–129].
While these results were discouraging, using MF59 in combination with small molecule
immunostimulators, particularly those known to induce a Th1 response such as CpG
(which has been previously used MF59 with encouraging results [130]), may improve effi‐
cacy with malaria antigens. In a recent study, five approved or clinically tested adjuvants
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(Alum, MF59®, GLA-SE, IC31®, and CAF01) were each combined with antigens from M.
tuberculosis, influenza, and chlamydia and compared in head-to-head mouse studies [100].
Of the five adjuvants tested, only MF59 and GLA-SE were able to induce inhibitory titers
to influenza; however, inhibitory titers with MF59 were >60% higher than with GLA-SE.
Note that MF59 formulations did not induce a Th1 immune response for any of the anti-
gens.
2.3.2. NanoStatTM platform
NanoStatTM (available from NanoBio Corporation) is an oil-in-water nanoemulsion composed
of soybean oil, ethanol, Tween 80, cetylpyridinium chloride, and water. Note that these
components are quite inexpensive as compared to those of some of the other adjuvants
described herein. The adjuvant activity of this nanoemulsion is dependent on the nanodroplet
structure and positive charge, which enables the penetration of the mucous layer, binding to
cell membranes, and cellular uptake [124, 131]. In mice, NanoStatTM has been shown to produce
systemic and mucosal immune responses including MyD88-independent Ab responses and
MyD88-dependent Th-1 and Th-17 cell-mediated responses [132]. While most of the published
research (including a Phase I clinical [133]) is with NanoStatTM formulated for intranasal
delivery, a formulation that contains the same components in proportions tailored for intra-
muscular administration is also available. These adjuvants can be combined with small
molecule immunostimulators. Currently, there are no published studies of NanoStatTM used
in combination with malaria antigens.
2.3.3. GLA-SE
GLA-SE (developed by IDRI) is an oil-in-water emulsion containing squalene and gluco-
pyranosyl lipid A (GLA), a synthetic Toll-like receptor 4 (TLR4) agonist that is similar to
MPLA. This adjuvant is known to generate both Th1 and Th2 immune responses. Multiple
clinical studies have been conducted with GLA-SE formulated vaccines [134–136] includ-
ing several with malaria antigens; however, results from the latter have not yet been pub-
lished. Preclinical studies with GLA-SE have been conducted with a number of malaria
vaccine candidates. As an example, in a study conducted with a full length PfCSP re-
combinant protein (produced by Pfenex) adjuvanted with GLA-SE, 50% sterile protection
was seen upon challenge in a mouse malaria model (Pb/PfCSP repeats and C-terminal re-
gion replacement) [92]. With a different full length PfCSP recombinant protein (produced
by WRAIR), 60% protection was seen upon challenge in a different mouse malaria model
(Pb/PfCSP full-length replacement) [137]. This adjuvant has also been used in combination
with PfCelTOS recombinant protein in preclinical studies, where a statistically significant
reduction in liver load was found in challenged mice [93]. A clinical study with PfCelTOS
formulated in GLA-SE has been conducted, but data have not yet been published (Clini-
calTrials.gov identifier: NCT01540474). Additionally, in a preclinical study with PvRII (re-
gion II of PvDBP) where moderate levels of in vitro erythrocyte binding inhibition (>50%)
was achieved with GLA-SE, slightly higher levels (>60%) were seen when GLA-SE was
combined with the TLR 7/8 agonist R848 [138].
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In a recent study, five approved or clinically tested adjuvants (Alum, MF59®, GLA-SE, IC31®,
and CAF01) were each combined with antigens from M. tuberculosis, influenza, and chlamydia
and compared in head-to-head mouse studies [100]. Of the five adjuvants tested, only GLA-
SE demonstrated statistically significant inhibition in all three challenge models. However, it
was not the best performer in any of the models.
2.3.4. Nutritive immune-enhancing delivery system (NIDS)
NIDS (developed by Epitogenesis, Inc.) is an oil-in-water nanoemulsion containing vitamin A,
a polyphenol-flavonoid, catechin hydrate, Tween 80, and mustard oil that were originally
developed to boost mucosal immune responses to a variety of antigens without triggering
inflammatory responses [139]. All the adjuvant components are generally regarded as safe
(GRAS) by the FDA and are available at GMP-grade. Note that these components are quite
inexpensive as compared to those of some of the other adjuvants described herein. The NIDS
platform allows modification of the NIDS components toward more Th1 or Th2 responses
[140]. In addition, this adjuvant can be administered systemically (e.g., IM injection) or
delivered via a mucosal route. Although this adjuvant has not yet be assessed in the clinic and
no preclinical studies have been published that use NIDS in combination with malaria
antigens, it is worth consideration regarding both its low cost and ability to adjuvant in the
absence of triggering an inflammatory response.
2.4. Small molecule adjuvants and immunostimulants
Several small molecule-based adjuvants and immunostimulators relevant to malaria vaccine
development are described herein. Note that although a number of TLR agonists have been
used in preclinical (and in some cases clinical) assessments of malaria vaccine candidates, these
have been thoroughly reviewed elsewhere [141, 142]. Such TLR agonists include MPLA/GLA
(TLR4 agonists), CpG oligodeoxynucleotides (ssDNA containing cytosines and guanines,
which are TLR9 agonists), Poly:IC (dsRNA, which is a TLR3 agonist), Pam3Cys (lipopeptide
and TLR1/2 agonist), as well as imiquimod and resiquimod (TLR 7/8 agonists), none of which
are detailed herein.
2.4.1. IC31® adjuvant platform
IC31® (developed by Valneva) is a two-component adjuvant comprised of a polycationic
peptide (poly-L-arginine) and ODN1a (a TLR9 agonist). Activity of this adjuvant includes
recruitment of MHC class II at the injection site as well as migration of antigen to the draining
lymph node [26]. The poly-L-arginine contributes to development of humoral and Th2 immune
responses [143], while ODN1a is a single-stranded DNA oligonucleotide that stimulates Th1
responses [144]. No studies of malaria vaccine candidates formulated IC31® have been
published. In a recent study, five approved or clinically tested adjuvants (Alum, MF59®, GLA-
SE, IC31®, and CAF01) were each combined with antigens from M. tuberculosis, influenza, and
chlamydia and compared in head-to-head mouse studies [100]. Of the five adjuvants tested,
IC31® elicited Th1 and Th2 immune responses and demonstrated a statistically significant
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reduction (but not the biggest reduction) of M. tuberculosis and C. trachomatis in challenge
models. This adjuvant has been assessed in the clinic [145–149].
2.4.2. 7DW8-5
7DW8-5 (developed by ADARC) is a glycolipid α-galactosylceramide (α-GalCer) analog
identified as part of structure-activity relationship (SAR) screening of α-GalCer analogs for
increased adjuvant activity as compared to the parent molecule [150]. 7DW8-5 induces Th1
immune responses by binding CD1d (nonclassical MHC proteins expressed on APCs that
present lipid antigens), stimulating natural killer cells, and inducing dendritic cell activation/
maturation as well as dendritic cell trafficking to the draining lymph node [150, 151]. This
adjuvant has been assessed in preclinical studies with several malaria vaccine candidates
including CSP, AMA-1, and irradiated sporozoites [151–153]. In formulations with 7DW8-5,
enhanced Th1 responses were found as well significantly reduced liver load [153] and a high
level of sterile protection (90%) upon challenge [151].
2.4.3. Saponins (QS-21)
Saponins (particularly QS-21), which can be extracted from the bark the Quillaja saponaria
Molina tree or be semisynthetic, are of interest because they have been shown to stimulate Th1-
type responses and production of antigen-specific cytotoxic T lymphocytes (CTLs) [88].
However, a major concern regarding use of QS-21 in malaria vaccines is instability at pH above
six and at elevated temperatures [88]. While it is possible to stabilize QS-21 (e.g., in lipids with
cholesterol), this small molecule is not recommended for malaria vaccines formulations
(intended for use in endemic regions) without assessments of stability at elevated temperatures
in the selected formulation.
3. Conclusions
In recent years, there has been a proliferation of novel and promising adjuvant and vaccine
delivery systems that together cast a wide net over the effector targets offered by our current
understanding of immune system’s pathways. Accordingly, this review surveys the field of
vaccine delivery platforms and adjuvants in the context of their potential utility for improving
the sterile or protective immunity conferred by malaria vaccine candidates. These technologies
have the potential to positively affect the induction of immune response elicited by a vaccine
candidate through more effective antigen delivery and presentation, ability to present multiple
epitopes/copies of epitopes, and mobilizing different components of the immune system
appropriate to the antigen and the malarial life-cycle stage being targeted.
Indeed, the judicious selection of vaccine delivery platforms and adjuvants is a necessary part
of the malaria vaccine development process. For example, RTS,S was tested with a range of
different adjuvants in both preclinical and clinical studies prior to section of AS01 for the
commercial formulation. Additionally, while many other malaria vaccine targets have since
been tested with AS01, none of these has achieved the same level of protective efficacy seen
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with RTS,S/AS01 [16]. These data demonstrate the necessity of evaluating malaria vaccine
targets with a range of delivery platforms and adjuvants prior to selection of the platform(s)/
adjuvant(s) for clinical testing. In addition, testing multiple formulations will likely be
necessary to sufficiently evaluate efficacy. In endemic regions, this process is compounded by
the parasite’s ability to hamper development of effective, long-lived immune responses as the
intersection of vaccination and infection varies greatly depending on the level of malaria
transmission. Several strategies for addressing these complications have been presented
including, (1) platforms capable of sustained antigen release, (2) adjuvants that function
without triggering inflammatory immune responses, and (3) use of blockage inhibitors to
reduce T cell exhaustion.
Additional considerations include affordability and cold-chain requirements. As the principal
target populations for vaccination against malaria are individuals residing in endemic regions,
primarily Africa and other developing countries, an effective vaccine must be relatively
inexpensive to manufacture, store, and deliver. Several of the enabling technologies presented
are relatively inexpensive. Additionally, some have the potential to stabilize the vaccine
formulation for room temperature storage and transport. However, accessibility is problematic
for several of these technologies, and there is a significant cost component regarding the
development process, particularly for the vaccine delivery platforms. Due to the complex
nature of malaria vaccine development, it is clear that a team approach capable of tapping into
expertise in the commercial, academic, government, and nonprofit sectors to efficiently
assemble the right combination of vaccine development and delivery technologies is critical
to success of malaria vaccine development strategies.
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